Acucela Secures Option to Exclusively Acquire Novel USC Retinal Technology

USC Stevens Center for Innovation is pleased to share news about an exclusive license newly executed for the rights to a novel retinal technology developed by researchers at USC.

Read more about the license with Acucela, a clinical-stage ophthalmology company, and how the new agreement will help to move forward the development of future therapeutics for sight-threatening eye diseases: http://www.businesswire.com/news/home/20161213006473/en/Acucela-Secures-Option-Exclusively-Acquire-Retinal-Technology.

–By USC Stevens staff, published December 14, 2016